Evoke Pharma, Inc.
EVOK
$10.93
$0.020.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 61.40% | 47.06% | 77.48% | 97.40% | 69.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.40% | 47.06% | 77.48% | 97.40% | 69.83% |
| Cost of Revenue | -1.92% | 304.10% | -55.03% | 100.85% | 197.99% |
| Gross Profit | 63.99% | 42.81% | 84.94% | 97.27% | 66.90% |
| SG&A Expenses | 38.97% | 37.54% | 36.88% | 25.88% | 22.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.61% | 40.69% | 35.38% | 26.33% | 24.43% |
| Operating Income | 11.51% | -27.40% | 13.29% | 36.77% | 19.81% |
| Income Before Tax | 11.90% | -23.97% | 17.32% | 39.98% | 22.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.90% | -23.97% | 17.32% | 39.98% | 22.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.90% | -23.97% | 17.32% | 39.98% | 22.52% |
| EBIT | 11.51% | -27.40% | 13.29% | 36.77% | 19.81% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 51.78% | 33.80% | 75.45% | 95.19% | 84.58% |
| Normalized Basic EPS | 51.77% | 33.79% | 75.45% | 95.19% | 84.58% |
| EPS Diluted | 51.78% | 33.80% | 75.45% | 95.19% | 84.58% |
| Normalized Diluted EPS | 51.77% | 33.79% | 75.45% | 95.19% | 84.58% |
| Average Basic Shares Outstanding | 82.68% | 87.25% | 236.77% | 1,147.38% | 402.48% |
| Average Diluted Shares Outstanding | 82.68% | 87.25% | 236.77% | 1,147.38% | 402.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |